Database Mining Detected a Cuproptosis-Related Prognostic Signature and a Related Regulatory Axis in Breast Cancer
Disease Markers · 19.10.2022 · 2022 · 1-22
DOI: 10.1155/2022/9004830 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease Markers, erschienen am 19.10.2022. Verfasst von Baohong Jiang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China. Hauptthemen laut MEDLINE: Breast Neoplasms, MicroRNAs, RNA, Long Noncoding, Apoptosis. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Program of the Hunan Provincial Department of Education, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Breast cancer is the frequent cause of disease burden related to cancer among women. It affects one in 20 women globally and up to one in eight women in high-income countries. Cuproptosis is a copper-induced modality of mitochondrial cell death that is involved in tumor proliferation and metastasis.
Methods
To construct a prognostic cuproptosis-related signature, LASSO Cox regression analysis was employed. Additionally, ceRNA was developed with an aim of exploring the possible lncRNA-miRNA-mRNA regulatory axis in breast cancer.
Results
The expression of FDX1, DLD, DLAT, LIAS, LIPT1, GLS MTF1, and PDHA1 was downregulated, while CDKN2A expression level was elevated in breast cancer in contrast with normal tissue. We furthermore reviewed the genetic mutation landscape of genes linked to cuproptosis in breast cancer. Prognosis analysis revealed poor OS and RFS rates in breast cancer patients with elevated levels of CDKN2A and PDHA1 and low levels of MTF1, DLD, LIPT1, and FDX1. We then constructed a cuproptosis-related signature with six genes (DKN2A, MTF1, PDHA1, DLD, LIPT1, and FDX1) for breast cancer, which predicted the OS rate with an accuracy that ranged from medium to high. Further analysis demonstrated a significant correlation between the cuproptosis-related prognostic signature and pTNM stage, MSI score, drug sensitivity, TMB score, and immune cell infiltration. Moreover, we identified the lncRNA XIST/miR-92b-3p/MTF1 regulatory axis for breast cancer.
Conclusion
Multiomics approaches were used to create a cuproptosis-related signature with six genes (DKN2A, MTF1, PDHA1, DLD, LIPT1, and FDX1) for breast cancer. We discovered the lncRNA XIST/miR-92b-3p/MTF1 regulatory axis for breast cancer, which has not yet been investigated previously.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
- Department of Medical Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
- Department of Pathology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
ORCID-Profile: Hongbo Zhu, Yuehua Li
Förderung
- Key Program of the Hunan Provincial Department of Education
- National Natural Science Foundation of China
Zitieren
APA
Jiang, B., Zhu, H., Feng, W., Wan, Z., Qi, X., He, R., Xie, L., & Li, Y. (2022). Database Mining Detected a Cuproptosis-Related Prognostic Signature and a Related Regulatory Axis in Breast Cancer. Disease Markers, 2022, 1-22. https://doi.org/10.1155/2022/9004830
Vancouver
Jiang B, Zhu H, Feng W, Wan Z, Qi X, He R, et al. Database Mining Detected a Cuproptosis-Related Prognostic Signature and a Related Regulatory Axis in Breast Cancer. Disease Markers. 2022;2022:1-22. doi:10.1155/2022/9004830
BibTeX
@article{Jiang2022,
author = {Jiang, Baohong and Zhu, Hongbo and Feng, Wenjie and Wan, Zhixing and Qi, Xiaowen and He, Rongfang and Xie, Liming and Li, Yuehua},
title = {Database Mining Detected a Cuproptosis-Related Prognostic Signature and a Related Regulatory Axis in Breast Cancer},
journal = {Disease Markers},
year = {2022},
volume = {2022},
pages = {1--22},
doi = {10.1155/2022/9004830}
}
EUVIMED